Login
$CTKB
$5.63 -$0.21 (3.6%) Live

$CTKB SEC Filings

Filed On Filing
13 Nov 2026 SCHEDULE 13G/A
12 Nov 2026 Form 4: Feuchtwang Ilan, Chief Legal Officer, Secretary

Granted 25,745 Restricted Stock Units

04 Nov 2026 10-Q
04 Nov 2026 8-K: Results of Operations and Financial Condition

FREMONT, Calif., November 4, 2026 (GLOBE NEWSWIRE) – Cytek Biosciences, Inc. (“Cytek Biosciences” or “Cytek”) (Nasdaq: CTKB), a leading cell analysis solutions company, today reported financial results for the third quarter ended Septemb...

03 Nov 2026 SCHEDULE 13G/A
29 Sep 2026 8-K: Amendments to Articles/Bylaws; Change in Fiscal Year

Section 1. Registered Office. The registered office of the corporation in the State of Delaware shall be in the City of Dover, County of Kent.

02 Sep 2026 144
24 Aug 2026 8-K: Regulation FD Disclosure; Other Events

FREMONT, Calif., August 21, 2026 (GLOBE NEWSWIRE) – Cytek Biosciences, Inc. (“Cytek Biosciences,” “Cytek,” or the “Company”) (Nasdaq: CTKB), a leading cell analysis solutions company, today announced that a jury in the United States Dist...

20 Aug 2026 Form 4: Jiang Wenbin, Director

Received 120,095 shares by exercise or conversion · Gave up 36,269 shares to cover exercise price or tax ($169K)

20 Aug 2026 Form 4: McCombe William D., Chief Financial Officer

Received 35,420 shares by exercise or conversion · Gave up 11,904 shares to cover exercise price or tax ($55.6K)

20 Aug 2026 Form 4: Muir Glenn P, Director

Received 3,086 shares by exercise or conversion

20 Aug 2026 Form 4: Holder Michael, Director

Received 2,181 shares by exercise or conversion

20 Aug 2026 Form 4: Chin Richard, Director

Received 6,107 shares by exercise or conversion

20 Aug 2026 Form 4: Yan Ming, Director

Received 33,270 shares by exercise or conversion · Gave up 8,088 shares to cover exercise price or tax ($37.8K)

12 Aug 2026 Form 4: Feuchtwang Ilan, Chief Legal Officer, Secretary

Granted 241,416 Restricted Stock Units · Granted 127,118 Employee Stock Option (right to buy)

06 Aug 2026 SCHEDULE 13G/A
05 Aug 2026 10-Q
05 Aug 2026 8-K: Results of Operations and Financial Condition

FREMONT, Calif., August 5, 2026 (GLOBE NEWSWIRE) – Cytek Biosciences, Inc. (“Cytek Biosciences” or “Cytek”) (Nasdaq: CTKB), a leading cell analysis solutions company, today reported financial results for the second quarter ended June 30,...

04 Aug 2026 SCHEDULE 13G
15 Jul 2026 8-K: Departure/Election of Directors or Officers; Compensation

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support